• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期神经内分泌肿瘤肝转移的非药物治疗选择

Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.

作者信息

Dermine Solène, Palmieri Lola-Jade, Lavolé Julie, Barré Amélie, Dohan Antony, Abou Ali Einas, Cottereau Anne-Ségolène, Gaujoux Sébastien, Brezault Catherine, Chaussade Stanislas, Coriat Romain

机构信息

Gastroenterology and Digestive Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France.

Department of Gastroenterology, Cochin Teaching Hospital, Université de Paris, 75014 Paris, France.

出版信息

J Clin Med. 2019 Nov 7;8(11):1907. doi: 10.3390/jcm8111907.

DOI:10.3390/jcm8111907
PMID:31703375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6912565/
Abstract

The incidence of liver metastasis in digestive neuroendocrine tumors is high. Their presence appears as an important prognostic factor in terms of quality of life and survival. These tumors may be symptomatic because of the tumor burden itself and/or the hormonal hyper-secretion induced by the tumor. Surgery is the treatment of choice for resectable tumors and metastasis. Nevertheless, surgery is only possible in a small number of cases. The management of non-resectable liver metastasis is a challenge. The literature is rich but consists predominantly in small retrospective series with a low level of proof. Thus, the choice of one technique over another could be difficult. Local ablative techniques (radiofrequency) or trans-catheter intra-arterial liver-directed treatments (hepatic artery embolization, chemo-embolization, and radio-embolization) are frequently considered for liver metastasis. In the present review, we focus on these different therapeutic approaches in advanced neuroendocrine tumors, results (clinical and radiological), and overall efficacy, and summarize recommendations to help physicians in their clinical practice.

摘要

消化性神经内分泌肿瘤肝转移的发生率很高。其存在似乎是生活质量和生存方面的一个重要预后因素。这些肿瘤可能因肿瘤负荷本身和/或肿瘤诱导的激素过度分泌而出现症状。手术是可切除肿瘤和转移灶的首选治疗方法。然而,手术仅在少数情况下可行。不可切除肝转移灶的管理是一项挑战。相关文献丰富,但主要是证据水平较低的小型回顾性系列研究。因此,在不同技术之间做出选择可能很困难。局部消融技术(射频)或经导管肝动脉靶向治疗(肝动脉栓塞、化疗栓塞和放射性栓塞)常用于肝转移的治疗。在本综述中,我们聚焦于晚期神经内分泌肿瘤的这些不同治疗方法、结果(临床和影像学)及总体疗效,并总结相关建议以帮助医生进行临床实践。

相似文献

1
Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.晚期神经内分泌肿瘤肝转移的非药物治疗选择
J Clin Med. 2019 Nov 7;8(11):1907. doi: 10.3390/jcm8111907.
2
Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.用于神经内分泌肝转移瘤的肝动脉内定向治疗
Semin Intervent Radiol. 2013 Mar;30(1):28-38. doi: 10.1055/s-0033-1333651.
3
Ablative therapies for liver metastases of digestive endocrine tumours.消化内分泌肿瘤肝转移的消融治疗
Endocr Relat Cancer. 2003 Dec;10(4):463-8. doi: 10.1677/erc.0.0100463.
4
Treatment options for unresectable neuroendocrine liver metastases.不可切除的神经内分泌肝脏转移瘤的治疗选择。
Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):357-69. doi: 10.1586/egh.11.60.
5
Therapeutic strategies for neuroendocrine liver metastases.神经内分泌性肝转移瘤的治疗策略
Cancer. 2015 Apr 15;121(8):1172-86. doi: 10.1002/cncr.28760. Epub 2014 Oct 1.
6
Arterial Therapies of Non-Colorectal Liver Metastases.非结直肠癌肝转移的动脉治疗
Viszeralmedizin. 2015 Dec;31(6):414-22. doi: 10.1159/000441689. Epub 2015 Dec 1.
7
Hepatic surgery for metastases from neuroendocrine tumors.神经内分泌肿瘤肝转移的肝手术治疗
Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. doi: 10.1016/s1055-3207(02)00076-5.
8
Liver metastasis from pancreatic neuroendocrine tumors after pancreaticoduodenectomy successfully treated by radiofrequency ablation combined with transcatheter arterial embolization: A case report.胰十二指肠切除术后胰腺神经内分泌肿瘤肝转移经射频消融联合经动脉化疗栓塞成功治疗:一例报告
Int J Surg Case Rep. 2020;77:147-151. doi: 10.1016/j.ijscr.2020.10.130. Epub 2020 Nov 1.
9
Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver.肝动脉栓塞联合肝消融治疗不可切除的结直肠癌肝转移灶。
Am Surg. 2012 Nov;78(11):1243-8.
10
GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.GEP-NETs 更新:介入放射学:在 GEP-NETs 肝转移治疗中的作用。
Eur J Endocrinol. 2015 Apr;172(4):R151-66. doi: 10.1530/EJE-14-0630. Epub 2014 Nov 10.

引用本文的文献

1
Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?肝细胞癌之外的化疗栓塞:我们可以治疗哪些肿瘤以及何时治疗?
Semin Intervent Radiol. 2024 Mar 14;41(1):27-47. doi: 10.1055/s-0043-1777716. eCollection 2024 Feb.
2
Surgical Management of Pancreatic Neuroendocrine Tumors.胰腺神经内分泌肿瘤的外科治疗
Cancers (Basel). 2023 Mar 28;15(7):2006. doi: 10.3390/cancers15072006.
3
Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET.

本文引用的文献

1
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with Lu-DOTATATE.基于 Lu-DOTATATE 的生长抑素受体靶向肽受体放射性核素治疗的 NANETS/SNMMI 操作标准。
J Nucl Med. 2019 Jul;60(7):937-943. doi: 10.2967/jnumed.118.230607.
2
Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis.中肠神经内分泌肿瘤肝转移的治疗:一项系统评价和荟萃分析
J Clin Med. 2019 Mar 22;8(3):403. doi: 10.3390/jcm8030403.
3
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.
生长抑素受体表达肿瘤体积与转移性 GEP-NET 患者健康相关生活质量的关系。
J Neuroendocrinol. 2022 Jun;34(6):e13139. doi: 10.1111/jne.13139. Epub 2022 Apr 29.
4
Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.晚期胰腺神经内分泌肿瘤患者接受药物/放射/肝脏靶向抗肿瘤治疗后耐药性疾病的预测因素:最新进展与争议
Cancers (Basel). 2022 Feb 28;14(5):1250. doi: 10.3390/cancers14051250.
5
Metastatic disease to the liver: Locoregional therapy strategies and outcomes.肝脏转移性疾病:局部区域治疗策略与疗效
World J Clin Oncol. 2021 Sep 24;12(9):725-745. doi: 10.5306/wjco.v12.i9.725.
6
Currently available treatment options for neuroendocrine liver metastases.目前针对神经内分泌性肝转移瘤的可用治疗方案。
Ann Gastroenterol. 2021;34(2):130-141. doi: 10.20524/aog.2021.0574. Epub 2021 Jan 16.
7
Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions.肝脏肿瘤的栓塞治疗:当前观点与未来方向
Dig Dis Interv. 2020 Jun;4(2):134-147. doi: 10.1055/s-0040-1712146. Epub 2020 May 25.
十二年肽受体放射性核素治疗随访。
J Nucl Med. 2019 Apr;60(4):524-529. doi: 10.2967/jnumed.118.215376. Epub 2018 Aug 16.
4
Treatment options for PNET liver metastases: a systematic review.胰腺神经内分泌肿瘤肝转移的治疗选择:系统评价。
World J Surg Oncol. 2018 Jul 14;16(1):142. doi: 10.1186/s12957-018-1446-y.
5
Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.肽受体放射性核素治疗与胃肠胰神经内分泌肿瘤的治疗:当前研究结果与未来展望
Nucl Med Mol Imaging. 2018 Jun;52(3):190-199. doi: 10.1007/s13139-018-0517-x. Epub 2018 Mar 28.
6
Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours.肝移植和多器官联合移植治疗晚期神经内分泌肿瘤患者。
World J Gastroenterol. 2018 May 28;24(20):2152-2162. doi: 10.3748/wjg.v24.i20.2152.
7
The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.肝移植在神经内分泌肿瘤肝转移治疗中的地位:利弊。
Rev Endocr Metab Disord. 2017 Dec;18(4):473-483. doi: 10.1007/s11154-017-9439-7.
8
Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases.神经内分泌肝脏转移瘤的检测和可切除性评估的形态学和功能影像学
Neuroendocrinology. 2018;106(1):74-88. doi: 10.1159/000479293. Epub 2017 Jul 21.
9
Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.神经内分泌肿瘤肝转移患者的肝移植:一项系统综述。
Surgery. 2017 Sep;162(3):525-536. doi: 10.1016/j.surg.2017.05.006. Epub 2017 Jun 16.
10
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.美国神经内分泌肿瘤患者的发病率、患病率和生存结局趋势。
JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.